Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237396 | 0.85 | PKM (0.56) | KMT2AMEN1HTT | |
| SCHEMBL30496480 | 0.85 | PKM (0.56) | KMT2AMEN1HTT | |
| SCHEMBL2091279 | 0.85 | KMT2A (0.53) | KMT2AMEN1HTTLDHAPOLB | |
| SCHEMBL3182347 | 0.83 | KMT2A (0.59) | KMT2AMEN1HTTHSD11B1POLB | |
| SCHEMBL2717301 | 0.83 | KMT2A (0.57) | KMT2AMEN1HTT | |
| SCHEMBL2336343 | 0.83 | TAS2R14 (0.43) | KMT2AMEN1HTTNPSR1HSD11B1 | |
| SCHEMBL3241093 | 0.82 | KMT2A (0.45) | KMT2AMEN1FFAR1KDM4E | |
| SCHEMBL3237393 | 0.81 | KMT2A (0.55) | KMT2AMEN1HTT | |
| Hydrochloric Acid SCHEMBL27633192 | 0.81 | KMT2A (0.55) | KMT2AMEN1HTT | |
| SCHEMBL9292841 | 0.81 | HSD11B1 (0.51) | KMT2AMEN1HTTNPSR1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-1305015-B1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2359819-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | Temple University - Of The Commonwealth System of Higher Education (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| EP-1292308-B1 | ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1328511-B1 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7056953-B2 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-06-06 | — | — | US | disclosed |
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | REDDY E PREMKUMAR (US) | 2003-02-20 | — | — | US | disclosed |
| EP-1173160-A4 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-02-19 | — | — | EP | disclosed |
| US-6486210-B2 | SUCH AS ENANTIOMORPHS OF 4-FLUOROSTYRYL-2,3,4,5,6-PENTAFLUOROBENZYLSULFONE; ANTIPROLIFERATIVE/ANTICANCER AGENTS | Temple University—Of the Commonwealth System of Higher Education | 2002-11-26 | — | — | US | disclosed |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-08-22 | — | — | US | disclosed |
| WO-2002028828-A1 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-04-11 | — | — | WO | disclosed |
| US-20020028818-A1 | Alpha, beta-unsaturated sulfones for treating proliferative disorders | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-07 | — | — | US | disclosed |
| EP-1173160-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001078733-A1 | ALPHA,BETA-UNSATURATED SULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078712-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000059495-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | PCNA, CDC25B, CCNB1 | KMT2A 3132/4885MEN1 1100/4885HTT 3878/4885 |
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | MKI67, MCL1, CCNA1 | KMT2A 2782/4885MEN1 733/4885HTT 3670/4885 |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | KMT2A 484/4885MEN1 979/4885HTT 2736/4885 |
| US-20020028818-A1 | Alpha, beta-unsaturated sulfones for treating proliferative disorders | QSOX1, CBR1, DEGS1 | KMT2A 3686/4885MEN1 3519/4885HTT 4341/4885 |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | HCCS, CCNO, HRAS | KMT2A 3413/4885MEN1 1662/4885HTT 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.